Results: Before starting brolucizumab, 23 eyes showed subretinal fluid, 8 both subretinal and intraretinal fluid, and 3 intraretinal fluid only. At the last visit, 22 eyes (64.7%) showed complete reabsorption of both intraretinal and subretinal fluid, whereas subretinal fluid was still present in 8 eyes (23.5%), and both intraretinal and subretinal fluid in 4 eyes (11.8%). The mean number of brolucizumab injections required to achieve complete fluid reabsorption was 2.8 ± 1.8. central foveal thickness decreased from 317.8 ± 109.3 µm to 239.8 ± 74.8 µm (P = 0.0005) and subfoveal choroidal thickness decreased from 399.3 ± 86.2 µm to 355.5 ± 92.7 µm at the end of the follow-up period (P = 0.0008). The mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.4 ± 0.2 to 0.3 ± 0.2 at 1 month after the first injection and remained stable at the same values at the end of the follow-up period (P = 0.04).

Lenovo - Open Source ThinkPad Thunderbolt 4 Workstation Dock - for Monitor/Notebook/Workstation - 230 W - Thunderbolt - 4 Displays Supported - 4K, 8K - 3840 x 2160, 7680 x 4320 - 4 x USB Type-A Ports - USB Type-A - 1 x USB Type-C Ports - USB Type-C - 40B00300USTHUNDERBOLT 4 WORKSTATION DOCK - TBT4 - HDMI 2 X DisplayPort 2 X TBT - GIGEManufacturer Part Number: 40B00300US

CompSource realizes that every product may have different return guidelines. Please see the policy below regarding this item.

Purpose: To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy.

Translational Relevance: Intravitreal brolucizumab may represent an option in patients with pachychoroid neovasculopathy complicating chronic central serous chorioretinopathy.

Part Number: 40B00300US Condition: New In Stock: 18   Real time availability

Please Note: Due to Lenovo's Policy this product is not available for return or exchange and must be handled with Lenovo Direct.

Marianna Carosielli, Adriano Carnevali, Matteo Fallico, Enza Pirozzi, Flavia Chiosi, Argyrios Chronopoulos, Pasquale Cucciniello, Marzia Affatato, Giuseppe Rapino, Roberto dell'Omo, on behalf of the BROCS study group, BROCS (BROlucizumab for the treatment of Central Serous chorioretinopathy) study group†; Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy. Trans. Vis. Sci. Tech. 2023;12(12):17. https://doi.org/10.1167/tvst.12.12.17.

All products are brand new and factory sealed unless otherwise stated. *** Disclaimer- Information is supplied by the Manufacturer. The image, including color, may differ from actual product appearance. CompSource, Inc. is not responsible for data. ***

Ground = FREE (EST. Arrival Date between Tue.Oct.22 - Fri.Oct.25)

Methods: Retrospective analysis of 34 eyes treated with intravitreal brolucizumab. Twenty-five eyes (73.5%) had been treated with other anti-vascular endothelial growth factor agents before switching to brolucizumab, whereas nine eyes were naïve. Outcome measures included the change of central foveal thickness and subfoveal choroidal thickness, evaluation of sub/intraretinal fluid on optical coherence tomography, and change in best-corrected visual acuity.

Copyright © 1999 - 2024 CompSource, Inc. All rights reserved. CompSource is not responsible for data, typographical, photographic or technical errors. Pricing & availability are subject to change without notice. 40B00300US | Lenovo® - Thinkpad Thunderbolt 4 Workstation Dock

Conclusions: Intravitreal brolucizumab is effective for the treatment of naïve and recalcitrant pachychoroid neovasculopathy.

We want this to be as easy and stress-free as possible. That's why we're offering to install everything for you. The expertly trained professionals from Buy It Installed provide high quality service and will get everything up and running with little to no hassle on your end.